Skip to main content
Clinical Trials/NCT01566318
NCT01566318CompletedNot Applicable

Depression Agency-Based Collaborative (Depression ABC)

University of Pittsburgh1 site in 1 country104 target enrollmentStarted: March 1, 2012Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
104
Locations
1
Primary Endpoint
Major depressive disorder

Study Overview

Brief Summary

Seniors who receive supportive services face a variety of psychosocial vulnerabilities that put them at risk for depression. One group with very high risk is older adults receiving aging services through Medicaid waiver programs. This 3-year research uses a randomized controlled clinical trial to assess the effectiveness of brief behavioral therapies (problem solving therapy [PST] and Brief Behavioral Therapy for Insomnia [BBTI]) to prevent depression in seniors receiving aging services.

Detailed Description

The research will determine (i) if a course of problem solving therapy (PST) and Brief Behavioral Therapy for Insomnia (BBTI), with boosters, reduces incidence of major depressive episodes over 12 months relative to usual care, and (ii) the extent to which behavioral therapies achieve these effects through enhancement of protective factors, such as greater self-efficacy, better targeting of services to address needs, and greater control over home environments.

Periodic blood draws will be used to assess biosignatures of depression. Guiding our investigations of pharmacogenetics, inflammation, and proteomics are synergistic interactions among the serotonergic system, the HPA axis, systemic inflammation, growth factors such as brain derived neuro-trophic factor (BDNF), psychosocial stressors, and vascular co-morbidity. Genetic variation in vasopressin receptors, potentially involved in both cardiovascular risk and social attachment, is also associated with recurrence of depression. Similarly, genetic variation in inflammation may influence antidepressant response and medical co-morbidity.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
60 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age => 60 years
  • •Modified Mini Mental State (3MS) Examination =>80
  • •Receiving aging services or difficulty with 1+ ADL/IADL
  • •PHQ-9 score > 0 and <= 9 (and question 1 or 2 is >0)

Exclusion Criteria

  • •Major depressive episode or anxiety disorder within 12 mo
  • •Ever diagnosed with bipolar disorder or schizophrenia
  • •Drug or alcohol use disorder within the past 12 months
  • •Currently taking antidepressants
  • •Currently taking antianxiety med >4x/week for past 4 weeks

Arms & Interventions

Problem solving therapy (PST)

Experimental

6-8 sessions of PST, with booster, delivered over 8 weeks

Intervention: Problem-Solving Therapy (Behavioral)

Usual care

No Intervention

Usual agency care, monitored for mental health services

Outcomes

Primary Outcomes

Major depressive disorder

Time Frame: 12 months

Patient Health Questionnaire score \> 9 with confirming diagnostic interview

Generalized anxiety disorder

Time Frame: 12 months

Generalized anxiety disorder score \>=10, and meets criteria for SCID or PRIME-MD diagnosis

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Steven M. Albert

Professor

University of Pittsburgh

Study Sites (1)

Loading locations...

Similar Trials